logo
  

Haemonetics Q4 Profit Falls, But Beats Estimates - Update

(Adds Outlook)

Looking ahead, for the full year, Haemonetics Corporation (HAE) expects to report adjusted income per share of $4.45 to $4.75, above the analysts' estimate of $4.4 per share.

Revenue is projected to grow 5 percent to 8 percent. Analysts, on average, expect the firm to generate revenue of $1.37 billion, for the year.

Q4 Results:

Haemonetics revealed earnings for fourth quarter that decreased from last year but beat the Street estimates.

The company's bottom line came in at $20.367 million, or $0.40 per share. This compares with $29.383 million, or $0.57 per share, in last year's fourth quarter.

Excluding items, Haemonetics Corp reported adjusted earnings of $46.016 million or $0.90 per share for the period.

Analysts on average had expected the company to earn $0.89 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 12.8% to $343.290 million from $304.416 million last year.

Haemonetics Corp earnings at a glance (GAAP) :

-Earnings (Q4): $20.367 Mln. vs. $29.383 Mln. last year.
-EPS (Q4): $0.40 vs. $0.57 last year.
-Revenue (Q4): $343.290 Mln vs. $304.416 Mln last year.

For comments and feedback contact: editorial@rttnews.com

Business News

Minutes of the latest Fed policy session dominated the economics scene this week. Find out what made policymakers give a “higher for longer” signal on interest rates. In Europe, the main news out this week was the inflation print from the U.K. Learn how the data was bad news for those hoping for an imminent rate cut from the Bank of England. Also, explore why New Zealand's central bank also hinted at a delay in its plans for interest rate reduction in future.

View More Videos
Follow RTT